0.02
+0.0031(+20.81%)
Currency In USD
Address
105 Bradford Road
Wexford, PA 15090
United States of America
Phone
724 934 6467
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
December 17, 2020
| Name | Title | Pay | Year Born |
| Mr. David Mehalick | Co-Founder, Chairman, Chief Executive Officer & Pres | 361,615 | 1969 |
| Ms. Christine Elise Sheehy | Co-Founder and Vice President of Compliance & Corporation Sec. | 225,999 | 1967 |
| Mr. Daniel Alexander Yerace | Co-Founder, Vice President of Operations & Director | 360,346 | 1983 |
| Mr. Gary R. Conte | Senior Vice President of Sales & Marketing | 0 | N/A |
| Mr. Brian Cogley M.B.A. | Chief Financial Officer | 0 | 1986 |
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.